USANA shares fall after Q1 beat as investors assess omni-channel shift

USANA Health Sciences (USNA) traded at $17.41 after its first-quarter earnings call, down 9.6% from $19.26 before the results, despite revenue coming in flat year over year and ahead of Wall Street expectations. Management said sequential improvement in its core nutrition business was driven by active customer growth, particularly in China, along with new product launches and investments in technology modernization. CEO Kevin Guest said the results reflected the company’s shift from a single-channel direct sales model to a diversified omni-channel health and wellness platform. Investor focus in coming quarters is expected to center on omni-channel sales growth, retail and international expansion for HYA and Rise Wellness, new products in women’s health, children’s health and active nutrition, and whether technology upgrades improve margins and customer experience.